A large number of studies have documented PRMT5 overexpression in cancers of different types and aggressiveness including B and T cell lymphoma [19, 20, 34], metastatic melanoma [35], neuroblastoma and glioblastoma [28, 36, 37], germ cell tumors [38], ovarian cancer [39], nasopharyngeal cancer [40], breast cancer [41], colorectal cancer [25], and gastric cancer [42]. Here, PRMT5 is linked to breast cancer.